Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report published on Monday morning,Benzinga reports. Chardan Capital currently has a $210.00 target price on the stock.

Several other research firms have also recently commented on PVLA. HC Wainwright raised their target price on Palvella Therapeutics from $200.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. UBS Group reissued a “buy” rating and issued a $143.00 price target on shares of Palvella Therapeutics in a research note on Monday, December 15th. Craig Hallum assumed coverage on Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price objective on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $184.87.

Palvella Therapeutics Trading Down 5.4%

PVLA stock opened at $114.23 on Monday. The firm has a market cap of $1.35 billion, a PE ratio of -43.43 and a beta of -0.30. The stock has a 50-day moving average price of $102.38 and a 200-day moving average price of $87.59. Palvella Therapeutics has a 1-year low of $18.23 and a 1-year high of $151.18.

Insider Activity at Palvella Therapeutics

In other news, Director Elaine J. Heron purchased 2,400 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, with a total value of $300,000.00. Following the purchase, the director owned 47,812 shares in the company, valued at $5,976,500. This represents a 5.28% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total value of $420,004.26. The SEC filing for this sale provides additional information. 20.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of large investors have recently modified their holdings of PVLA. Group One Trading LLC increased its stake in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Palvella Therapeutics by 11.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after buying an additional 433 shares during the last quarter. Archer Investment Corp bought a new position in shares of Palvella Therapeutics in the third quarter valued at $28,000. Bank of America Corp DE lifted its stake in shares of Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after buying an additional 515 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Palvella Therapeutics by 8.7% during the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock valued at $690,000 after buying an additional 528 shares during the last quarter. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.